Welcome to our dedicated page for Hepion Pharmaceuticals SEC filings (Ticker: HEPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hepion Pharmaceuticals SEC filings document a Delaware issuer that has shifted from chronic liver disease drug development to precision diagnostics, including licenses and asset arrangements for hepatocellular carcinoma liquid biopsy assays and other diagnostic tests. Current reports record material agreements, intellectual property licenses, unregistered equity sales, leadership changes, and the company’s OTCQB-era public-company status.
Proxy and 8-K filings cover board elections, auditor ratification, equity incentive plan amendments, officer and director transitions, separation arrangements, capital-structure disclosures, and stockholder voting matters. The records also provide historical context for earlier rencofilstat-related development, listing compliance actions, reverse stock split activity, and governance disclosures.
Hepion Pharmaceuticals, Inc. reported insider-related buying of its common stock. Entities associated with Executive Chairman and 10% owner Vincent S. LoPriore completed open-market purchases at $0.04 per share on April 21, 2026.
Invictus Capital Advisors Pension Plan bought 1,250,000 shares, bringing its holdings to 6,250,000 shares, while Gravitas Capital LP bought 5,000,000 shares, resulting in 5,000,000 shares held. Footnotes state Mr. LoPriore has voting and investment power over both entities’ positions.
Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.
Hepion Pharmaceuticals interim CEO Gary S. Stetz reported an indirect open-market purchase of 1,250,000 shares of common stock at $0.04 per share. The shares are held through the Stetz Belgiovine CPA 401K F/B/O Gary S. Stetz account, and this filing shows total indirect holdings of 1,250,000 shares after the transaction.
Hepion Pharmaceuticals, Inc. entered into securities purchase agreements with accredited investors for a private placement of common stock. The company agreed to sell an aggregate of 17,500,000 shares of common stock at an offering price of $0.04 per share, for gross proceeds of $700,000.
The transaction closed on April 21, 2026. The shares were issued in an unregistered offering relying on exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, meaning they cannot be freely resold in the United States without registration or a valid exemption.
Hepion Pharmaceuticals, Inc. reported leadership changes and a separation package for its former chief executive. The company entered into a separation agreement with former CEO Dr. Kaouthar Lbiati effective April 13, 2026, following her earlier resignation for personal reasons.
Under this agreement, Dr. Lbiati will receive $225,000, a $30,625 payment representing the pro‑rated portion of her potential cash bonus, and reimbursement of her COBRA health insurance payments for six months. She also agreed to a general release and confidentiality provisions. On the same date, Dr. Lbiati resigned as a director of the company, leaving both her executive and board roles.
Hepion Pharmaceuticals announced that Chief Executive Officer Dr. Kaouthar Lbiati resigned for personal reasons, effective immediately on March 16, 2026. The Board moved quickly to reconfigure leadership, naming Gary Stetz as interim CEO and a director the same day.
The Board also appointed Vincent LoPriore as Executive Chairman and added Sireesh Appajosyula and Chase LoPriore as directors. The company states there are no special arrangements behind these appointments and no family relationships between the new leaders and existing directors or executive officers.
Hepion Pharmaceuticals’ annual report outlines a major strategic shift and significant financial risk. The company has exited its prior focus on liver drug rencofilstat, winding down the ASCEND-NASH trial in 2024 and selling all rencofilstat-related assets to Panetta Partners in May 2025 for a nominal amount, with only contingent value rights retained for shareholders.
Hepion is repositioning as a medical diagnostics company, in-licensing CE‑marked tests for celiac disease, respiratory multiplex, H. pylori and hepatocellular carcinoma from New Day Diagnostics in May 2025, and liver disease diagnostic intellectual property from Cirna Diagnostics in February 2026. The New Day arrangement resulted in total consideration of $815,045, all expensed after impairment.
The company has an accumulated deficit of $246.1 million as of December 31, 2025, and discloses substantial doubt about its ability to continue as a going concern, expecting to exhaust available cash during the third quarter of 2026 without additional capital. It raised approximately $8.2 million in 2025 and $4.3 million in 2024 but now has only two employees and no internal manufacturing or commercial infrastructure, relying on third parties for development and future production.
Hepion Pharmaceuticals entered a material intellectual property license agreement with Cirna Diagnostics, adding a liver disease diagnostic asset to its portfolio. The company will pay an upfront $50,000, certain patent expenses, up to $2,350,000 in development milestones, up to $4,500,000 in sales milestones, and low single-digit royalties on net sales.
Hepion also highlighted a novel circulating tumor RNA biomarker assay for earlier diagnosis and surveillance of hepatocellular carcinoma in high-risk patients, reinforcing its strategic shift toward liquid biopsy-based cancer diagnostics under new leadership.
Hepion Pharmaceuticals (HEPA) filed its Q3 2025 10‑Q, showing a continued business pivot from liver drug development to medical diagnostics. The company reported a Q3 net loss of $472,506 and a nine‑month net loss of $7,620,965. Operating expenses fell sharply as research and development dropped to zero for the quarter, while general and administrative expense was $527,902.
Cash was $2,321,078 at September 30, 2025, with total liabilities of $415,808 and stockholders’ equity of $3,324,432. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital. Shares outstanding were 11,620,317 as of November 12, 2025.
Hepion in‑licensed diagnostic tests from New Day Diagnostics on May 9, 2025, paying $525,000 cash and $270,629 in stock, with up to $17.15 million in potential milestones; it recorded a $402,746 impairment. On May 26, 2025, it sold all rencofilstat assets to Panetta Partners for a nominal amount, with CVRs tied to future FDA approval and sales milestones. Earlier, the company raised approximately $9.0 million (January 23, 2025), repaid $2.9 million notes, effected a 1‑for‑50 reverse split, and transitioned trading to OTCQB after Nasdaq delisting.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) filed a Form 8-K to disclose the resignation of Chief Financial Officer and director John Brancaccio. His departure, attributed to personal reasons, is effective June 30, 2025. The filing, made pursuant to Item 5.02, notes that Kaouthar Lbiati signs as Interim CFO. No additional management changes, compensation details, or financial data were provided.